
IndraLab
Statements
reach
"(A) NRP1 protein in the NRP1–VEGF-A complex; (B) VEGF-A ligand in the NRP1–VEGF-A complex; (C) NRP1 protein in the NRP1–S1 complex; (D) NRP1 protein in the NRP1–R complex; (E) NRP1 protein in the NRP1–HRG complex; (F) NRP1 protein in the NRP1–RRRR complex; (G) NRP1 protein in the NRP1–RRAK complex; (H) NRP1 protein in the NRP1–RRAR complex; (I) NRP1 protein in the NRP1–RRAH complex; (J) NRP1 protein in the NRP1–TKPR complex; (K) NRP1 protein in the NRP1–TKPPR complex; (L) NRP1 protein in the NRP1–PPR complex; (M) NRP1 protein in the NRP1–PPRV complex; (N) NRP1 protein in the NRP1–PPR(V) complex; (O) NRP1 protein in the NRP1–EG0029 complex; (P) NRP1 protein in the NRP1– RRAA complex; (Q) NRP1 protein in the NRP1–RAAR complex; (R) NRP1 protein in the NRP1–ARAR complex.Figure 3: The percentage of simulation time during which intermolecular polar contacts were retained between NRP1 and the peptides in three independent 1 μs runs of: (A) NRP1–RRAK; (B) NRP1–RRAH; (C) NRP1–RRRR; (D) NRP1–RRAR; (E) NRP1–VEGF-A; (F) NRP1–S1; (G) NRP1–R; (H) NRP1–HRG."
sparser
"Figure 3: The percentage of simulation time during which intermolecular polar contacts were retained between NRP1 and the peptides in three independent 1 μs runs of: (A) NRP1–RRAK; (B) NRP1–RRAH; (C) NRP1–RRRR; (D) NRP1–RRAR; (E) NRP1–VEGF-A; (F) NRP1–S1; (G) NRP1–R; (H) NRP1–HRG."
sparser
"Blocking VEGFA 165 binding to NRP1 using a selective NRP1 inhibitor, ATWLPPR Peptide TFA (trifluoroacetic acid) (42), inhibited migration, although this effect did not reach statistical significance and NRP1 inhibition did not significantly affect VEGFA 165 -induced proliferation ( fig."
reach
"Treatment of mice in utero (E12.5-E16.5) with an antibody that blocks Sema3A binding to Nrp-1, but not with an antibody that blocks VEGF-A binding to Nrp-1, resulted in a complex phenotype of impaired lymphatic vessel function, enhanced perivascular cell coverage and abnormal lymphatic vessel and valve morphology."
sparser
"Figure 5: The percentage of simulation time during which intermolecular hydrophobic contacts were retained between NRP1 and the peptides in three independent 1 μs runs of: (A) NRP1–RRAR; (B) NRP1–RRAK; (C) NRP1–RRAH; (D) NRP1–VEGF-A; (E) NRP1–S1; (F) NRP1–PPR; (G) NRP1–PPRV; (H) NRP1– PPR(V); (I) NRP1–TKPPR; (J) NRP1–TKPR; (K) NRP1–RRAA; (L) NRP1–RAAR; (M) NRP1–ARAR."
reach
"(A) NRP1 protein in the NRP1-VEGF-A complex; (B) VEGF-A ligand in the NRP1-VEGF-A complex; (C) NRP1 protein in the NRP1-S1 complex; (D) NRP1 protein in the NRP1-R complex; (E) NRP1 protein in the NRP1-HRG complex; (F) NRP1 protein in the NRP1-RRRR complex; (G) NRP1 protein in the NRP1-RRAK complex; (H) NRP1 protein in the NRP1-RRAR complex; (I) NRP1 protein in the NRP1-RRAH complex; (J) NRP1 protein in the NRP1-TKPR complex; (K) NRP1 protein in the NRP1-TKPPR complex; (L) NRP1 protein in the NRP1-PPR complex; (M) NRP1 protein in the NRP1-PPRV complex; (N) NRP1 protein in the NRP1-PPR(V) complex; (O) NRP1 protein in the NRP1-EG0029 complex; (P) NRP1 protein in the NRP1-RRAA complex; (Q) NRP1 protein in the NRP1-RAAR complex; (R) NRP1 protein in the NRP1-ARAR complex."
sparser
"Blocking VEGFA 165 binding to NRP1 using a selective NRP1 inhibitor, ATWLPPR Peptide TFA (trifluoroacetic acid) ( xref ), inhibited migration, although this effect did not reach statistical significance and NRP1 inhibition did not significantly affect VEGFA 165 -induced proliferation (fig."
reach
"Importantly, although inhibition of the VEGF-A binding to Nrp-1 did not influence lymphatic vessel development, the formation of small blood vessels was impaired, in agreement with the previously reported effects of this antibody 24 - therefore confirming the activity of the antibody."
reach
"Blocking of Vegf binding to Nrp1 using a specific antibody that leaves Vegf binding to Vegfr2 intact XREF_BIBR does not phenocopy the retinal angiogenesis defects in Nrp1 mutants described here, and Nrp1 promotes activation of intracellular c-abl activation in a VEGF independent manner XREF_BIBR, further supporting the idea that Nrp1 may affect other pathways that trigger tip cell formation."
reach
"Alternatively, the interaction of NRP-1, VEGF-A, and SARS-CoV2 may be responsible for part of the presented symptoms 11 : blocking the binding site of VEGF-A to NRP-1, as described for SARS-CoV2 spike protein, could ameliorate or prevent proper pain sensation in affected patients."
sparser
"After docking and two rounds of similarity search computations, we identified 4 compounds that inhibit the biotinylated VEGF-A₁₆₅ binding to recombinant NRP-1 with Ki of about 10 μM. These compounds contain a common chlorobenzyloxy alkyloxy halogenobenzyl amine scaffold that can serve as a base for further development of new NRP-1 inhibitors."
sparser
"VEGF-A interacts with NRP-1 and this leads to enhanced VEGF-A interaction with VEGFR, leading to enhanced angiogenesis. xref – xref Consistent with this role, NRP-1 overexpression increases blood vessel formation, xref and inactivation causes abnormal vasculature formation leading to embryonic lethality. xref NRP-1 is expressed in various human tumors, including prostate cancer, breast cancer, melanoma and pancreatic adenocarcinoma. xref – xref In some model systems, NRP-1 expression increases angiogenesis and tumor formation; xref , xref however, how NRP-1 regulates tumor formation is not well understood."
reach
"Alternatively, NRP and VEGFA complexes binding to FLT1 can also prevent endothelial cell migration and vascular development so there are potentially many check points that are present within the testis to prevent over-vascularization to ensure development of the seminiferous cords."
sparser
"Here, we demonstrated that both regorafenib and SC-78 could decrease the endogenous level of VEGF-A and the inhibition of secreted VEGF-A would further reduce the binding of VEGF-A to receptor NRP-1, which might lead to increased binding of SEMA3A and NRP-1 and reduce the migration of breast cancer cells."
sparser
"Though TKPR has been reported to disrupt the NRP1-VEGF interface (von Wronski, 2006), the results of the present study cannot conclusively support that finding given the inconsistency of binding affinity scores across the three simulations of NRP1-TKPR (-23.67 ± 11.80 kcal/mol, -67.33 ± 5.31 kcal/mol, -51.48 ± 19.13 kcal/mol) and NRP1-VEGF-A (-85.81 ± 18.66 kcal/mol, -67.34 ± 11.27 kcal/mol, -82.07 ± 18.59 kcal/mol)."
sparser
"To exclude that impaired VEGFR2 phosphorylation simply reflects a reduced affinity of NRP1 cyto for VEGF-A 165 , we used an established method that tests binding of NRP1 ligands such as alkaline phosphatase-conjugated VEGF-A 165 to NRP1-expressing axons and vessels in vivo ( xref )."
reach
"It is of interest that we found fewer blood vessel capillaries in anti-Nrp-1B treated pups at day P5.5 (XREF_SUPPLEMENTARY), indicating that the formation of smaller blood vessels is impaired when VEGF-A binding to Nrp-1 is blocked, in line with previously reported effects of this antibody 24."
sparser
"Thus, all the isoforms can bind the two main VEGFA tyrosine kinase receptors, VEGFR1 (FLT1) and VEGFR2 (KDR, previously also known as FLK1), while NRP1 binds with higher affinity the larger VEGFA isoforms, such as VEGFA165 and VEGFA189, compared to VEGFA121 by interacting with the heparin binding domain encoded by exon 7, even though the interaction between VEGFA and NRP1 also involves the exon 8 encoded epitope, which is common to all the isoforms [ xref , xref , xref , xref ]."
reach
"Alternatively, the interaction of NRP-1, VEGF-A, and SARS-CoV2 may be responsible for part of the presented symptoms11: blocking the binding site of VEGF-A to NRP-1, as described for SARS-CoV2 spike protein, could ameliorate or prevent proper pain sensation in affected patients.11Obviously, we cannot completely rule out other reasons for the observed hypoalgesia, abnormal QST, and reduced intraepidermal fiber density."
sparser
"As it was mentioned already, the amino acid Asp320 is very important for NRP1 to interact with different ligands and VEGF-A xref , xref , as well as for the CendR region in the SARS-CoV-2 xref , xref , therefore, the region between the amino acids Thr316, Asp320, Ser346, Thr349 and Tyr353 has a very important role for the S1 region of SARS-CoV-2 to interact with NRP1; in this study was carried out a docking directed to amino acids in the b1 region reported in the NRP1 (Thr316, Asp320, Ser346, Thr349 and Tyr353) xref , that is important to interact with the S-Protein (S1 region) of SARS-CoV-2 xref , since it has been shown that by preventing this interaction, the infectious process caused by this virus could be reduced xref , xref , xref ."
| PMC
sparser
"Blocking of Vegf binding to Nrp1 using a specific antibody that leaves Vegf binding to Vegfr2 intact xref does not phenocopy the retinal angiogenesis defects in Nrp1 mutants described here, and Nrp1 promotes activation of intracellular c-abl activation in a VEGF-independent manner xref , further supporting the idea that Nrp1 may affect other pathways that trigger tip cell formation."
sparser
"The well-documented NRP1/VEGF-A blocker EG00229 (Jarvis et al., 2010) was also studied to compare its NRP1 interaction with that of VEGF-A. Thus, in this study, to explore the stability and binding interactions of CendR peptides, seventeen systems were studied – VEGF-A, 13 peptides, a lone arginine, an arginine analogue and an NRP1 inhibitor (Table 1
and Figure 1C)."
sparser
"The well-documented NRP1/VEGF-A blocker EG00229 ( xref ) was also studied to compare its NRP1 interaction with that of VEGF-A. Thus, in this study, to explore the stability and binding interactions of CendR peptides, seventeen systems were studied – VEGF-A, 13 peptides, a lone arginine, an arginine analogue and an NRP1 inhibitor ( xref and xref C)."
sparser
"To further analyse its role in arthritis-induced angiogenesis, we investigated whether NRP-1 function is required for the induction of endothelial cell migration by arthritic paw homogenates applying a neutralising antibody that specifically blocks the binding of VEGF121 and VEGF164 to NRP-1 [ xref , xref ]."
sparser
"Figure 1: (A) Comparison of the binding modes of VEGF-A164 (in orange stick representation) and SARS-CoV-2 (in green stick representation) CendR motifs by superimposing VEGF-A-NRP1 (PDB ID: 4DEQ; [17] NRP1 in orange cartoon representation) and SARS-CoV-2-NRP1 (PDB ID: 7JJC; [6] NRP1 in green cartoon representation) complexes. (B) Zoomed view representing SARS-CoV-2 CendR binding mode into the b1 domain of NRP1, highlighting interactions with the key amino-acid residues (in green stick representation)."
sparser
"The potency of compound 2 in inhibiting VEGF-A binding to NRP1 was thus very similar to that of the bicyclic peptide compound 1 , which inhibits 125 I-VEGF-A binding to PAE/NRP1 and tumor cells with IC 50 values of 2−3 μM and inhibits 125 I-VEGF-A binding to HUVECs with an IC 50 of 20 μM.( xref )"
sparser
"Further studies of the shortest active fragment of A7R led to a more elaborate branched peptidomimetic, Lys(hArg)-Dab-Pro-Arg, which was a stronger inhibitor of VEGF-A 165 binding with NRP-1, as determined by an in vitro ELISA assay, and was more stable in human serum compared to A7R [ xref ]."
sparser
"Although these data support the role of NRP1 as a positive modulator of VEGF-A signalling, the fact that VEGF-A binding to NRP1 is dispensable for vascular permeability in vivo and that combining anti-NRP1 with anti-VEGF-A blocking antibodies has a synergistic effect on tumour angiogenesis and growth, suggests that NRP1 also promotes VEGF-A independent signalling [ xref ]."
reach
"17 Novel drug compounds which act as NRP1 antagonists could therefore exhibit their anticancer effects in three different ways : blocking tumor angiogenesis by blocking the NRP1 and VEGF-A interaction, 18 preventing tumor cell migration by binding to NRP1, 19 and reducing Treg or macrophage mediated suppression of the immune response."
sparser
"Furthermore, treatment with anti-NRP1 blocking antibodies preventing NRP1 binding to VEGF-A, partially decreases VEGF-A-induced EC proliferation and AKT, ERK1/2 and p38 MAPK phosphorylation compared to treatment with an anti-VEGF-A antibody which completely abrogated these VEGF-A-induced responses [ xref ] ( xref )."
reach
"Treatment of mice in utero with an antibody that blocks Sema3A binding to Nrp-1, but not with an antibody that blocks VEGF-A binding to Nrp-1, resulted in reduced lymphatic vessel function, abnormal morphology of the collecting lymphatic vessels and valves, and aberrant SMC coverage of lymphatic vessels."
reach
"No information on the spontaneous mutations of the amino-acid residues in the CendR binding pocket of NRP1 could also be found.Disrupting the key protein-protein interactions between NRP1 and VEGF-A at the b1 CendR binding site has long been the focus of drug discovery efforts, particularly for cancer therapy."
reach
"The finding that expression of the Y297A and D320A NRP1 mutants reduced high-affinity VEGF-A 165 binding to endothelial cells and VEGF-A 165 stimulation of endothelial cell migration and tubulogenesis in a coculture model provides strong evidence that VEGF-A 165 binding to NRP1 plays an important role in migratory responses important for angiogenesis."
sparser
"VEGFR-1 (also known as Flt1 ) is considered to be a decoy receptor that limits VEGF-A availability for VEGFR-2 and therefore activation and signaling of the VEGF-A/VEGFR-2 axis (decoy - or - sink hypothesis). xref , xref VEGF-A also binds to semaphorin receptor NRP1, xref a single spanning non–tyrosine kinase transmembrane protein that functions as a VEGFR-2 co-receptor."
reach
"Correspondingly, all molecular descriptors were calculated for these compounds and they were considered part of the small molecule set.Since one objective of inhibiting the VEGF-A/NRP-1 interaction is disruption of pain signals, the full therapeutic effect will require drug exposure in the central nervous system (CNS)."
sparser
"NRP1 has also been implicated in tumor growth and angiogenesis; inhibition by a blocking antibody that prevents VEGF-A binding to NRP1 enhanced the antitumor effects of the inhibitory anti-VEGF-A antibody, bevacizumab, in mouse xenograft models.( xref ) As an alternative to biological therapeutics, small molecule inhibitors of NRP1 function would be desirable, but development of protein−protein interaction inhibitors is not a trivial task. xref , xref We utilized the bicyclic peptide 1 , corresponding to the C-terminal 28 amino acids of VEGF-A 165 (Figure xref ) as a starting point for small molecule design."
sparser
"In this article, we have identified residues essential for VEGF-A 165 binding to NRP1, which constitute part of the putative binding pocket for VEGF-A 165 in the NRP1 b1 domain, defined by computational analysis of the b1 domain structure, and inferred from the crystal structure of the b1 domain."
reach
"Correspondingly, all molecular descriptors were calculated for these compounds
and they were considered part of the small molecule set.Since one objective of inhibiting the VEGF-A/NRP-1 interaction is disruption of pain
signals, the full therapeutic effect will require drug exposure in the central nervous
system (CNS)."
sparser
"It is reported the crystallographic structure of the interaction between NRP1 with EG00229 (PDB:3I97); which is demonstrating that the main amino acids important are: Thr316, Asp320, Ser346, Thr349 and Tyr353 in NRP1 to interact with EG00229, in which the same corresponding amino acids are identified when NRP1 interacts with VEGF-A 33."
| PMC
sparser
"Conversely, blocking NRP1 binding to VEGF-A with anti-NRP1 blocking antibodies abrogating VEGF-A binding to NRP1 but not to VEGFR2, reduces VEGF-induced EC migration, proliferation, vessel sprouting and neovascularisation in the eye, although to a lesser extent compared to VEGF blocking antibodies [ xref ]."
sparser
"Interaction between NRP and VEGF-A 165 -HBD was also observed in affinity chromatography protocols where His 6 -tagged NRP1 b1 domain that was bound to the Ni-NTA column was used to capture un-tagged VEGF-A 165 -HBD from the solution; the two proteins co-eluted upon addition of the imidazole."
sparser
"Though TKPR has been reported to disrupt the NRP1-VEGF interface ( xref ), the results of the present study cannot conclusively support that finding given the inconsistency of binding affinity scores across the three simulations of NRP1-TKPR (-23.67 ± 11.80 kcal/mol, -67.33 ± 5.31 kcal/mol, -51.48 ± 19.13 kcal/mol) and NRP1-VEGF-A (-85.81 ± 18.66 kcal/mol, -67.34 ± 11.27 kcal/mol, -82.07 ± 18.59 kcal/mol)."
reach
"VEGF-A binds VEGFR1 and VEGFR2 homodimers, VEGFR1/2 and VEGFR2/3 heterodimers, as well as Nrp1 homodimers; VEGF-B and PGF bind VEGFR1 homodimers, VEGFR1/2 heterodimers and Nrp1 homodimers; and VEGF-C and VEGF-D bind VEGFR2 and VEGFR3 homodimers, VEGFR2/3 heterodimers and Nrp2 homodimers."
sparser
"To
clarify the nature of these interaction results on cross-sectional cognition,
stratified analyses showed that in APOE -ε4 carriers,
higher expression of NRP1 (β=−0.176, p=0.034) and VEGFA (β=−0.027, p=0.019) were associated
with worse global cognition scores; whereas in APOE -ε4
non-carriers, higher NRP1 (β=0.112, p=0.003) expression
predicted better global cognition scores."
reach
"Thus, all the isoforms can bind the two main VEGFA tyrosine kinase receptors, VEGFR1 (FLT1) and VEGFR2 (KDR, previously also known as FLK1), while NRP1 binds with higher affinity the larger VEGFA isoforms, such as VEGFA165 and VEGFA189, compared to VEGFA121 by interacting with the heparin binding domain encoded by exon 7, even though the interaction between VEGFA and NRP1 also involves the exon 8 encoded epitope, which is common to all the isoforms [58,59,60,61]."
sparser
"According to the literature data, the heptapeptide A7R is known to be an effective antagonist of the VEGF-A 165 binding with NRP-1 and to show in vivo anti-angiogenic properties [ xref ], whereas the Lys(hArg)-Dab-Pro-Arg peptidomimetic is much more active (IC 50 = 0.2 μM) than the heptapeptide A7R (IC 50 = 5.9 μM [ xref ]), with a stability half-life in human serum that is nearly 2 days [ xref , xref ]."
sparser
"In contrast, a study in chick revealed that VEGFR2 and Nrp1 are expressed in cranial NCCs while VEGF-A is expressed in the surface ectoderm adjacent to the rhombomere 4 NCC migratory route, and furthermore, that the VEGF-A-Nrp1 interaction was required for proper cranial NCC invasion from the rhombomere 4 migratory stream into branchial arch 2 ( xref )."
sparser
"The suitability of the binding pocket to accommodate different ligands with the CendR terminals is evident from the comparison of the crystal complexes of VEGF-A 164 -NRP1 and SARS-CoV-2-NRP1 ( xref A), which show remarkable similarities in the binding mode of their CendR sequences."
sparser
"Figure 2: Root mean square fluctuation (RMSF) of protein Cα atoms obtained from three independent runs of the different peptides bound to NRP1. (A) NRP1 protein in the NRP1–VEGF-A complex; (B) VEGF-A ligand in the NRP1–VEGF-A complex; (C) NRP1 protein in the NRP1–S1 complex; (D) NRP1 protein in the NRP1–R complex; (E) NRP1 protein in the NRP1–HRG complex; (F) NRP1 protein in the NRP1–RRRR complex; (G) NRP1 protein in the NRP1–RRAK complex; (H) NRP1 protein in the NRP1–RRAR complex; (I) NRP1 protein in the NRP1–RRAH complex; (J) NRP1 protein in the NRP1–TKPR complex; (K) NRP1 protein in the NRP1–TKPPR complex; (L) NRP1 protein in the NRP1–PPR complex; (M) NRP1 protein in the NRP1–PPRV complex; (N) NRP1 protein in the NRP1–PPR(V) complex; (O) NRP1 protein in the NRP1–EG0029 complex; (P) NRP1 protein in the NRP1– RRAA complex; (Q) NRP1 protein in the NRP1–RAAR complex; (R) NRP1 protein in the NRP1–ARAR complex."
reach
"XREF_BIBR Notably, a previous research has reported that peptides inhibiting the binding of VEGF-A and NRP -1 could inhibit breast cancer progression, XREF_BIBR and two groups have demonstrated that a monoclonal antibody targeting neuropilin-1 or a neuropilin-1 antagonist could exert anticancer effects in breast cancer via in vitro and in vivo experiments."
sparser
"A library of 5 × 10 5 compounds was screened for specifically targeting this site; nine chemical series were reported with lead- or drug-like physical and chemical properties, out of which six compounds effectively disrupted VEGF-A–NRP-1 interaction, and all nine inhibited VEGF-A triggered VEGFR2 phosphorylation."
sparser
"M. W. Parker et al. reported the first detailed picture of the structural basis for the binding of NRP-1 and VEGF-A. The binding interface involved regions encoded by both exons 7 and 8 of VEGF-A. Exon 7 encoded residues primarily govern selectivity, whereas exon 8 encoded residues mainly mediate high-affinity binding [ xref ]."
| PMC
reach
"The potency of compound 2 in inhibiting VEGF-A binding to NRP1 was thus very similar to that of the bicyclic peptide compound 1, which inhibits 125 I-VEGF-A binding to PAE and NRP1 and tumor cells with IC 50 values of 2-3 muM and inhibits 125 I-VEGF-A binding to HUVECs with an IC 50 of 20 muM."
reach
"Effects of Semaphorins and Neuropilin -1 17, however, involve a more complicated process and have been shown to function as pro - angiogenesis stimuli (VEGF-A 165 binding to NRP-1 and VEGFR-2 and Plexin-A1 or 2) or facilitate migration (Np-1/Np-2/VEGFR-1/Plexin-A1/2 when bound by VEGF-A (165, 145, 121), VEGF-B and PlGF-2)."
sparser
"Thus, all the isoforms can bind the two main VEGFA tyrosine kinase receptors, VEGFR1 (FLT1) and VEGFR2 (KDR, previously also known as FLK1), while NRP1 binds with higher affinity the larger VEGFA isoforms, such as VEGFA165 and VEGFA189, compared to VEGFA121 by interacting with the heparin binding domain encoded by exon 7, even though the interaction between VEGFA and NRP1 also involves the exon 8 encoded epitope, which is common to all the isoforms [58,59,60,61]."
reach
"Our data further showed that expression of the Y297A NRP1 mutant prevented VEGF-A 165 -induced complex formation between NRP1 and KDR, indicating that VEGF-A 165 binding to NRP1 is essential for formation of NRP1 and KDR heterodimers either alone or as homodimers or oligomers with WT NRP1, and that these heterocomplexes may be rapidly destabilized by subsequent VEGF-A 165 binding to KDR."